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Anti-inflammatory interleukin-10 genotype protects dialysis as the elevation of C-reactive protein (CRP) are pre-
patients from cardiovascular events. dictive for cardiovascular events in otherwise healthy
Background. Inflammatory processes play an important role men and that aspirin is more beneficial in patients withfor the progression of atherosclerosis. This can be studied par-
microinflammation than in those without [1]. The patho-ticularly well in patients with chronic renal failure who are on
genetic link between inflammation and atherosclerosishemodialysis, as they show systemic inflammation due to ure-
mia and dialysis while suffering from premature mortality sec- seems to be the monocyte/macrophage cell type. These
ondary to rapidly progressing atherosclerosis. Interleukin (IL)-10 cells produce proinflammatory cytokines that induce the
is a regulatory cytokine that limits inflammatory processes. The hepatic synthesis of acute phase proteins, among themquantitative production of IL-10 is subject to genetic variation
CRP. On the other hand, these cells infiltrate atheroscle-based on polymorphisms in the promoter of its gene. We tested
rotic plaques, differentiate into tissue macrophages andthe hypothesis that the IL-10 genotype, by influencing the ca-
pacity to compensate for dialysis-induced systemic inflamma- foam cells, and attract further leukocytes by their cyto-
tion, determines the risk for cardiovascular complications. kines [2]. The more active these cells are, the faster the
Methods. Three hundred chronic hemodialysis patients were
atherosclerotic lesion may grow. Although progressiongenotyped for the polymorphic bases at positions 1082 and
and instability of vascular plaques are associated with819 of the IL-10 promoter sequence. They were prospectively
followed for a mean of 20.2  7.3 months. End-points of the detectable signs of inflammation [3, 4], it is not clear
study were major events related to cardiac, cerebrovascular or whether inflammation enhances the growth of the lesion
peripheral artery disease. or whether the instability of the lesion leads to enhanced
Results. The1082A* allele, which is associated with low pro-
systemic cytokine release.duction of the cytokine IL-10 and elevated markers of systemic
Patients with chronic renal failure suffer from rapidlyinflammation such as C reactive protein, was predictive for a
higher cardiovascular morbidity (relative risk for cardiovascu- progressing atherosclerosis that accounts for a large part
lar events 2.76, 95% confidence interval 1.31 to 4.17, P 0.004) of premature deaths [5]. Studying the issue of inflamma-
compared to the 1082G* genotype. tion in atherosclerotic disease in this particular patientConclusion. The IL-10 genotype influences the risk for car-
group is highly interesting since they combine the highdiovascular events in hemodialysis patients and allows the def-
risk for vascular events with the presence of a well docu-inition of a high risk group. The data provide further evidence
for a causal role of systemic inflammation for progressive ath- mented chronic systemic inflammation [6]. The latter is
erosclerosis in dialysis patients. induced by uremia and the frequent contacts between
blood and artificial surfaces during hemodialysis treat-
ment. Although the high levels of cytokines in this pa-
Recently, increasing attention has focused on the tient group are most likely not caused by vascular lesions,
pathogenetic role of inflammatory processes for athero- the association between elevated CRP and cardiovascu-
sclerotic disease. The Physician’s Health Study showed lar mortality has been shown even more clearly in dialysis
that indicators of low-level systemic inflammation such patients than in the general population [7].
The cascade of inflammatory factors leading to an acute
phase reaction is counter-regulated by the anti-inflam-Key words: arteriosclerosis, hemodialysis, C-reactive protein, progres-
sive renal disease, chronic renal failure, uremia. matory cytokine interleukin-10 (IL-10) [8]. This leuko-
cyte derived factor limits an inflammatory response toReceived for publication November 20, 2001
pathogens and is responsible for its physiologic shut-and in revised form March 25, 2002
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tor- (TNF-)], IL-10 seems to be the most important lar mortality was determined from the patient’s files, the
cause of death was taken from the death certificate andfactor to down-regulate acute phase responses. Similar
to many other cytokines, the amount of IL-10 that is autopsy reports were evaluated whenever possible.
produced upon a definite stimulus is subject to genetic
Genotyping of the IL-10 promoter polymorphismsregulation [9]. Polymorphic bases in the promoter of
the IL-10 gene lead to a high or low production of this DNA was extracted from 500L of venous blood anti-
coagulated with ethylenediaminetetraacetic acid (EDTA).cytokine. Therefore, inflammatory activation may be
higher in patients with an IL-10 ‘low-producer’ genotype The cells were lysed by proteinase K (Sigma Chemicals,
Deisenhofen, Germany) for 10 minutes at 56C. Furtherand vice versa. Given the key role of IL-10 in the regula-
tion of the inflammatory activation, we studied whether preparation was done using the QIAamp DNA Blood
Mini Kit (Qiagen, Hilden, Germany) according to thethere is an association of the IL-10 genotype with the
risk of cardiovascular events in the high-risk group of manufacturer’s protocol.
Genotype analysis was done by highly specific ARMS-chronic hemodialysis patients.
PCR (amplification refractory mutation system [10]).
This protocol is based on a polymerase chain reaction
METHODS
(PCR) using primers ending 3 with the complementary
Patients base for the single polymorphic base in the promoter
sequence. Stringency of reaction parameters assures thatThree hundred chronic hemodialysis patients from
seven German dialysis centers were randomly selected a PCR product is only formed when the 3 base matches.
We used a Hybaid PCR Express thermocycler (Hybaidand enrolled in this prospective observational study. The
patients suffered from chronic renal failure due to dia- Ltd., Teddington, UK) and the Perkin Elmer AmpliTaq
Gold Polymerase (Applied Biosystems, Weiterstadt, Ger-betic nephropathy (N  75), glomerulonephritis (79),
polycystic disease (32), interstitial disease (26), nephro- many). Each 50 L reaction contained 5 L DNA solu-
tion, 1 U Taq Polymerase, 5 L 10 buffer, 3.5 mmol/Lsclerosis (23), or other diagnoses (19). The renal diagno-
sis was unknown in 46 patients. The patients were on MgCl2, 400mol/L d-adenosine 5-triphosphate (dATP),
d-guanosine 5-triphosphate (dGTP), d-cytidine 5-tri-hemodialysis treatment for at least one month (range 1
to 326 months, mean 64.1  69.3 months). Patients with phosphate (dCTP) and d-ribothymidine 5-triphosphate
(dTTP), and 0.2 mol/L of both primers. To achieve theongoing immunosuppressive treatment or known malig-
nancy were excluded. Patients were neither selected for high specificity we used the following cycler program: ac-
tivation of polymerase at 95C for seven minutes, andtheir history of cardiovascular disease nor for their medi-
cation. Treatment modalities were left to the choice of thereafter 30 cycles at 95C for one minute of denatur-
ation, 64C for one minute 45 seconds annealing and elon-the institution where the patient was treated. Of the pa-
tients, 34% were treated by cellulosic membranes, 37% gation, finally once at 72C for a ten-minute elongation.
Each genotyping was done by five reactions: 	-actinby modified cellulose (hemophan), and 29% by synthetic
membranes (mainly polyamide and polysulfone). Mem- as an internal control (661 bp product length), two reac-
tions for both polymorphic bases at position 1082brane types were equally distributed among genotype
groups. Demographic data of the patients are given in (258 bp product length) and 819 (233 bp product
length). Primer sequences for the IL-10 polymorphismsTable 1. All individuals gave informed consent and the
study was approved by the local ethics board. [10, 11] and 	-actin [12] were used as published earlier.
In eight cases direct sequencing of the promoter region
Cardiovascular events starting from position 1103 to 886 as well as from
position 857 to 537 was used to control PCR-basedPatients were enrolled into the trial between October
and December 1999. They were followed until trans- genotyping.
The PCR product was visualized by gel electrophoresisplantation, death, or December 2001 unless lost to fol-
low-up. Follow-up was on average 20.2  7.3 months on a 1.5% agarose gel stained with ethidium bromide
on an electronic documentation system (Kodak EDAS(range 1.0 to 26.0 months). Cardiovascular events were
defined as myocardial infarction (primary event in 10 120/1D Image Analysis Software; Life Technologies,
Karlsruhe, Germany).patients), the need for coronary angioplasty or coronary
bypass surgery (18 patients), cerebral ischemia (transient
Markers of inflammationischemic attack (TIA), prolonged reversible ischemic
neurologic defect (PRIND), or persisting apoplexia with Laboratory parameters of systemic inflammation were
tested in all patients at study entry. CRP was detectedexclusion of hemorrhage (11 patients), the need for pe-
ripheral artery angioplasty, bypass surgery, or amputa- by an immunologic turbidimetry, serum albumin by ne-
phelometry and fibrinogen by a clotting test. In 15 pa-tion due to peripheral angiopathy (11 patients), or death
due to cardiovascular causes (23 patients). Cardiovascu- tients with the IL-10 high-producer and 15 patients with
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typing PCR result. Table 1 indicates the characteristics
of these patients compared to those homozygous for the
base A (1082A*; 36% of all patients) and the heterozy-
gous patients (42%). There were no differences in terms
of sex distribution, age, duration of dialysis therapy, or
medication at study entry. Also, the number of patients
who already had cardiovascular events in their history
at the beginning of the study was the same in all groups
(Table 1). Furthermore, there were no differences in the
distribution of underlying renal diseases between the
genotype groups (data not shown). Since the cardiovas-
cular risk is different for diabetic and non-diabetic pa-
tients, it is particularly important to note that IL-10 geno-
type frequencies were essentially the same in both these
groups. Genotyping for the base at 819 revealed that
165 patients were homozygous for 819C*, 24 patients
were homozygous for 819T* and 111 patients wereFig. 1. Result of the polymerase chain reaction (PCR) based genotyp-
ing. This representative gel electrophoresis shows the genotyping in heterozygous.
two patients. The presence of a PCR product indicates that the base
at the 3 terminus of the primer matched, that is, the respective comple- Markers of systemic inflammation
mentary base is present in the promotor of the IL-10 gene of the patient.
Presence of both PCR products for one locus indicates a heterozygous The IL-10 genotype was closely associated with signs
patient. The fifth band each is the house keeping gene 	-actin as an of systemic inflammation in dialysis patients. Table 2 lists
internal control (Ct). The left part of the gel shows a patient heterozy-
the C-reactive protein, fibrinogen and albumin at studygous at 1082 and homozygous for 819C*. The right part shows a
patient homozygous for 1082A* and 819T. entry as markers of dialysis-associated inflammation.
CRP and fibrinogen were higher and albumin was lower
in the1082A* group compared to the1082G* group,
reflecting the fact that the IL-10 ‘low-producer’ patients
the low producer genotype, CRP was detected during six (1082A*) cannot down-regulate inflammation as effec-
months by blood sampling during the first week of each tively. Figure 2 shows a longitudinal observation in 15 pa-
month before a dialysis session. In both patient groups, tients each with an IL-10 ‘high-’ or ‘low-producer’ geno-
eight patients were diabetics. None of the 30 patients type. CRP was detected during the first week of each month
had overt infectious complications at study entry, how- regardless of whether the patient had intercurrent com-
ever, they were not excluded from the analysis when plications. The IL-10 ‘low-producer’ genotype was per-
complications developed during the six month period. missive for more frequent elevations of the acute phase
protein compared to the IL-10 ‘high-producer’ genotype.
Statistical analysis
Relationship between the IL-10 genotype andData management and statistical analysis were done
cardiovascular events
with the Prism statistical software (Version 3.02; Graph-
During the follow-up period, 84 cardiovascular eventspad, San Diego, CA, USA) and the SPSS Software (Ver-
occurred in 73 of the 300 dialysis patients during 6060sion 10.0; SPSS Inc., Chicago, IL, USA). Frequency counts
patient-months, which is an event rate of 1.4 per 100were compared by 
2 analysis. Continuous data are re-
patient-months. Figure 3 compares the proportions of pa-ported as mean  standard deviation and compared by
tients being free from cardiovascular events grouped ac-the nonparametric Kruskal-Wallis test. Survival curves
cording the 1082 allele of the IL-10 gene. While thewere calculated by the Kaplan-Meier method and com-
average observation period was the same in all threepared by Cox proportional hazards regression. Results
groups, more cardiovascular events were observed in thewere regarded as significant at P  0.05.
1082A* group (45 events, 2.0 events per 100 patient-
months) than in the heterozygous (30 events, 1.2 per 100
patient-months) or the 1082G* group (10 events, 0.8RESULTS
per 100 patient-months). By Cox analysis, the relative risk
Genotyping of the IL-10 promoter polymorphisms for cardiovascular events was 2.76 [95% confidence inter-
Twenty-two percent of 300 patients with chronic renal val (95% CI) 1.31 to 4.17] in the 1082A* compared to
failure were homozygous for the base G at position1082 the 1082G* group and the event-free survival was sig-
(1082G*) upstream of the coding sequence of the IL-10 nificantly lower in the 1082A* group than in the
1082G* group (P  0.0052; Fig. 3). There was alsogene. Figure 1 shows a representative example of a geno-
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Table 1. Demographic data and therapy at study entry
1082G* Heterozygous 1082A* P
N 66 125 109
Mean follow-up months 20.17.5 19.77.7 20.86.5 0.78
Gender % male 62.1% 47.2% 56.9% 0.11a
Age years 64.513.9 62.214.4 60.614.7 0.23
Number of months on dialysis 69.069.7 65.661.9 73.776.8 0.94
Diabetics 22.7% 25.6% 25.7% 0.89a
Patients with history of
cardiovascular events 36.4% 30.4% 30.3% 0.65a
Patients with smoking history 65.2% 62.4% 68.9% 0.58a
Therapy with ASA 27.2% 25.6% 33.9% 0.35a
Therapy with CSI 18.2% 12.0% 16.5% 0.45a
Therapy with ACE-I 21.2% 22.4% 26.6% 0.65a
Total cholesterol mg/dL 202.849.5 209.545.1 204.450.7 0.45
Parathyroid hormone pg/mL 200.5217.1 203.4269.0 200.4240.5 0.91
Dialysis patients are grouped according to their IL-10 genotype. Patients homozygous for the IL-10 ‘high-producer’ genotype 1082G* are compared to patients
homozygous for the ‘low-producer’ genotype 1082A*, and the heterozygous patients. Abbreviations are: ASA, acetylsalicylic acid; CSI, cholesterol synthesis
inhibitors; ACE-I, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Comparison of the three groups was by the Kruskal-Wallis test.
Comparison of 1082G* vs. 1082A* only did not reveal any statistically significant differences.
a Chi-square test
Table 2. Markers of systemic inflammation at study entry
1082G* Heterozygous 1082A*
CRP mg/L 9.0 (0.0–41.0)b 12.0 (0.0–84.0) 15.0 (0.0–89.0)b
Fibrinogen mg/dL 410 (204–601)a 418 (315–784) 442 (213–623)a
Albumin mg/dL 38 (30–44)a 37 (29–46) 37 (29–45)a
CRP and fibrinogen were detected as positive acute phase proteins and albu-
min as a negative acute phase protein. Data are given as median (range).
a P  0.05, b P  0.01, 1082G* vs. 1082A* by the Kruskal-Wallis test
a significant difference between the 1082A* and the
heterozygous group (P 0.011). Genotyping of the poly-
morphism at position 819 upstream of the coding se-
quence did not reveal any relation to the number of car-
diovascular events (data not shown). Table 3 shows the
type of events that occurred in the genotype groups.
The relationship between cardiac, cerebral or peripheral
artery events was the same in patients with different
IL-10 genotypes.
The Cox proportional hazards model showed that the
effect of the IL-10 genotype on the cardiovascular event
rate was independent of age, sex, dialysis center, serum
cholesterol, serum albumin, and parathyroid hormone.
The only other parameter besides the genotype being
closely associated with event-free survival was CRP (P
0.027 by Cox analysis). This fits with the observation
that the IL-10 genotype was related to signs of chronic
systemic inflammation in these dialysis patients.
Mortality in patients with a different IL-10 genotype
During the follow-up period 72 patients died: 19 in
the 1082G* group (18.8%), 30 in the heterozygous
Fig. 2. C-reactive protein (CRP) values of 15 patients with the IL-10
group (24%) and 23 in the 1082A* group (21.1%). “high-producer” (A) or “low-producer” (B) genotype during the first
week of each month taken prior to a dialysis treatment regardlessTherefore, the annual mortality rate for our hemodialysis
whether the patient had complications. The IL-10 “low-producer” geno-patients was 14.3%. Cardiovascular complications were
type seems to be permissive for more frequent elevations of CRP. Mean
the cause of death in 53% of cases. There was no differ- CRP in the “low-producer” group was 18.2 1.6 mg/L and in the “high-
producer” group 8.4  1.7 mg/L (P  0.002, Mann-Whitney test).ence in all-cause mortality between patients with the
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Fig. 3. Survival without cardiovascular events
in dialysis patients with different alleles at po-
sition1082 of the IL-10 gene promoter. Sym-
bols are: (solid thick line) 1082G; (solid thin
line) heterozygous; (thick dashed line)1082A.
Cardiovascular events were defined as described
in the Methods section. Patients homozygous
for 1082A* showed a significantly shorter
event-free survival compared to patients with
the 1082G* genotype (P  0.004, all three
patient groups; Cox proportional hazards
analysis).
Table 3. Types of cardiovascular events and their relative tients with an average or elevated risk for cardiovascular
frequencies in the IL-10 genotype groups
disease, while the absolute values usually stayed within
Type of event 1082G* Heterozygous 1082A* the normal range [1]. In contrast, dialysis patients fre-
N 66 125 109 quently show chronically elevated CRP levels even in
Cardiac 5 (56%) 16 (67%) 26 (65%) the absence of infectious complications [7].
Cerebral 2 (22%) 6 (25%) 7 (18%)
The causes of inflammation in dialysis patients havePeripheral 2 (22%) 2 (8%) 7 (18%)
Total 9 24 40 been studied in detail. Uremia and renal replacement
therapy including blood-membrane contacts and com-There were no differences in the relative frequencies of the types of cardiovas-
cular events between the IL-10 genotype groups. For this analysis only the plement activation are the most relevant factors that
primary cardiovascular events during follow-up were counted. There were 8
induce the production of pro-inflammatory cytokines bypatients with two subsequent events and one patient with 3 events.
monocytes [16]. However, there are large interindividual
differences in the extent of inflammation that cannot be
explained by renal disease or its treatment. We recently
different IL-10 genotypes. In contrast, a higher mortality showed that the extent of chronic inflammation in dial-
occurred from cardiovascular causes in IL-10 1082A* ysis patients is inversely related to the individual’s pro-
patients compared to 1082G* patients (P  0.047; duction of the regulatory cytokine IL-10 [6, 17]. Further-
Fig. 4). There was no single cause of mortality that ap- more, strong genetic influences on the levels of IL-10
peared more frequently in the1082G* group; however, found in healthy persons [9] also could be confirmed in
there was a trend toward more mortality due to infec- dialysis patients [12]. The genetic determination of the
tious complications in the ‘high-producer’ group (5 cases amount of IL-10 produced upon a definite stimulus may
compared to 3 cases in the 1082A* group).
explain, at least in part, the large interindividual differ-
ences in the inflammatory activation of these patients.
DISCUSSION Interleukin-10 is one among a few cytokines that op-
poses the action of multiple proinflammatory mediators.The incidence of cardiovascular events and cardiovas-
Its physiologic role is the limitation and final shut-downcular mortality are high among patients with chronic
of the inflammation, such as after the invasion of patho-renal failure. The annual incidence of myocardial in-
gens. It down-regulates the production of monocyte-farction is two to three times higher in hemodialysis
derived cytokines [8]. We show here that the polymor-patients and occurs earlier in life than in an age-matched
phism at position 1082 of the IL-10 gene promoter,general population [13]. Several studies recently showed
which determines a “high-” or “low-producer” pheno-a relation between signs of chronic inflammation, for
type, is predictive for the risk of cardiovascular eventsexample, IL-6 [14] or CRP [7, 15] and cardiovascular
in hemodialysis patients. This effect is independent frommortality [7, 14] or sonographically monitored signs of
many accompanying factors such as cholesterol level,atherosclerosis [15] in patients with chronic renal failure.
patient age, medication, or the underlying renal diseases.This reflects, at a higher level, the association between
However, it is closely related to the extent of chronicmicroinflammation and progression of atherosclerotic
systemic inflammation as judged by the CRP level.disease that has been found in patients with normal renal
The reason for the predictive value of the IL-10 geno-function [1, 3]. In the latter, highly sensitive assays for
CRP were needed to detect the differences between pa- type for cardiovascular events might be that patients
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Fig. 4. All-cause mortality (A) and mortality
from cardiovascular causes (B) in relation to
the IL-10 genotype. Symbols are: (solid thick
line) 1082G; (solid thin line) heterozygous;
(thick dashed line) 1082A. While all-cause
mortality was the same in the patient group,
cardiovascular mortality was clearly higher in
the IL-10 “low-producer” patients than the
“high-producer” group (P  0.047).
homozygous for the IL-10 “high-producer” genotype duce, the more likely is growth and instability of the
plaque. High expression of anti-inflammatory factors1082G* can limit uremia- and dialysis-induced chronic
inflammation more efficiently than those with the “low- such as IL-10, however, seems to limit the progression of
a lesion. This has been shown in several animal models:producer” genotype 1082A*. Our data on CRP and
albumin confirm this hypothesis and indicate the pres- cardiac allograft vasculopathy is thought to be an exam-
ple of inflammation-induced highly progressive athero-ence of enhanced systemic inflammation in patients with
the IL-10 “low-producer” genotype that is permissive for sclerosis. IL-10 knockout mice suffer from much more
severe vascular lesions due to graft rejection than allo-frequent elevations of acute phase proteins. These find-
ings are a further strong hint on a causal role of systemic grafted mice that can produce the anti-inflammatory cy-
tokine [18]. In addition, the susceptibility to atheroscle-inflammation for the rapidly progressing atherosclerosis
in patients on hemodialysis treatment. We did not detect rosis induced by high cholesterol diet was 30-fold
enhanced in IL-10 deficient mice [19].any influence of the819 polymorphism, which is in line
with our recent finding that, at least in dialysis patients, A role for IL-10 also has been shown in human coro-
nary heart disease. Patients with unstable angina pectoristhe 1082 polymorphism is associated with detectable
differences in the amount of IL-10 produced by mono- had lower IL-10 serum levels than those with stable an-
gina indicating a protective role of the anti-inflammatorycytes, while the 819 polymorphism is not [12].
The role of inflammation in the pathogenesis of ath- cytokine [20]. Although these findings suggested that the
IL-10 gene polymorphism might influence the risk forerosclerosis was suggested by Ross [2], who pointed out
that many of the cells infiltrating the atherosclerotic cardiovascular events, a recent study could not prove a
predominance of a “low-producer” genotype in patientsplaque are either lymphocytes or derived from mono-
cytes. The more proinflammatory factors these cells pro- with myocardial infarction [21]. An explanation for the
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